Skip to main content

Table 2 Study endpoints at 6 weeks

From: Empagliflozin prevents doxorubicin-induced myocardial dysfunction

 ControlsDOX groupDOX + EMPA groupDOX + FURO group
Weight, g23.18 ± 1.821.45 ± 2.722.5 ± 2.121.8 ± 2.4
Glucose, mg/dl200.6 ± 40166.6 ± 72205.5 ± 39170.5 ± 50
Systolic pressure, mmHg121 ± 15102 ± 37119 ± 20*105 ± 33
Diastolic pressure, mmHg76 ± 1141 ± 1065 ± 28*60 ± 24*
LVEF, %68.7 ± 5%49.24 ± 861.30 ± 11*55.79 ± 11
LVFS, %39.4 ± 3%24.70 ± 533.08 ± 8*28.62 ± 8
LVEDd, mm3.11 ± 0.13.98 ± 0.43.89 ± 0.33.80 ± 0.7
LVESd, mm1.93 ± 0.52.98 ± 0.42.67 ± 0.52.73 ± 0.5
IVS, mm0.81 ± 0.0010.69 ± 0.0040.77 ± 0.001*0.77 ± 0.005*
PW, mm0.78 ± 0.0010.71 ± 0.0050.76 ± 0.0130.76 ± 0.014
Longitudinal strain (LS),%− 24.1 ± 4%− 13.93 ± 5− 17.52 ± 3*− 16.1 ± 3.5
Circumferential strain (CS), %− 29.9 ± 8%− 15.91 ± 6− 25.75 ± 6*− 15.8 ± 3.3
Radial strain (RS), %46.0 ± 7%26.7 ± 1324.0 ± 526.1 ± 4
E/A1.6 ± 0.11.7 ± 0.21.6 ± 0.21.5 ± 0.1
E/Eʹ41.1 ± 2.277.3 ± 3.561.1 ± 5.7*59.4 ± 4*
  1. Values are mean ± SD, or n (%)
  2. LVEF left ventricular ejection fraction, LVFS left ventricular fractional shortening, IVS interventricular septum, PW posterior wall
  3. *p < 0.05 compared to DOX